Ameritas Investment Partners Inc. grew its holdings in shares of PTC Therapeutics by 3.6% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/05/20/citigroup-boosts-ptc-therapeutics-nasdaqptct-price-target-to-70-00/

Finally, Credit Suisse Group reissued a “neutral” rating and issued a $48.00 price target on shares of PTC Therapeutics in a research note on Wednesday, February 22nd.

Source: https://www.etfdailynews.com/2023/04/23/insider-selling-ptc-therapeutics-inc-nasdaqptct-insider-sells-38093-28-in-stock/

New York Life Investment Management LLC purchased a new position in shares of PTC Therapeutics in the first quarter valued at approximately $475,000.

Source: https://www.etfdailynews.com/2023/08/23/california-state-teachers-retirement-system-lowers-stake-in-ptc-therapeutics-inc-nasdaqptct/

Nisa Investment Advisors LLC grew its holdings in PTC Therapeutics by 26.0% during the third quarter.

Source: https://www.etfdailynews.com/2023/03/13/38694-shares-in-ptc-therapeutics-inc-nasdaqptct-bought-by-putnam-investments-llc/

Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.

Source: https://www.prnewswire.com/news-releases/germany-cell-and-gene-therapy-market---focused-insights-2023-2028-sector-to-reach-3-44-billion-by-2028-at-a-40-cagr-301784069.html

Royal Bank of Canada reiterated a “sector perform” rating and issued a $49.00 price target on shares of PTC Therapeutics in a report on Thursday, July 20th.

Source: https://www.etfdailynews.com/2023/08/23/bank-of-new-york-mellon-corp-decreases-holdings-in-ptc-therapeutics-inc-nasdaqptct/

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

Source: https://investorplace.com/2023/10/algn-stock-alert-align-technology-announces-250m-stock-buyback-program/